Tinnitus in patients on therapy with proton pump inhibitors (PPI) and in PPI non-users

被引:2
|
作者
Pirodda, Antonio [1 ]
Raimondi, Maria Chiara [1 ]
Cicero, Arrigo Francesco Giuseppe [2 ]
Rosticci, Martina [2 ]
Rinaldi, Elisa Rebecca [2 ]
Bellacosa, Lara [2 ]
Stanghellini, Vincenzo [2 ]
Borghi, Claudio [2 ]
机构
[1] Univ Bologna, Dept Expt Diagnost & Specialty Med, Via Massarenti,9, I-40138 Bologna, Italy
[2] Univ Bologna, Dept Med & Surg Sci, Bologna, Italy
关键词
proton pump inhibitors; inner ear disorders;
D O I
10.3109/21695717.2014.902554
中图分类号
R36 [病理学]; R76 [耳鼻咽喉科学];
学科分类号
100104 ; 100213 ;
摘要
Objective: We wished to observe the prevalence of tinnitus in subjects on therapy with proton pump inhibitors (PPI). A possible favourable effect of the commercially available proton pump inhibitors (PPI) on inner ear disorders was recently outlined. In order to investigate this possibility the prevalence of tinnitus (an indicator of labyrinthine sufferance in general terms) among PPI users and non-users was analysed. Study design: An observational study on the prevalence of tinnitus among PPI users and non-users was carried out. Between June 2012 and March 2013 a cohort of consecutive patients who were referred to S. Orsola-Malpighi University Hospital of Bologna for various non-audiological disorders was included in the study. Each patient was instructed to complete an anonymous validated questionnaire on hearing problems. The Ethics Committee of S. Orsola Malpighi Hospital had been informed about collection of the data. Results: In the age class 60-69 years there was a statistically significant lower prevalence of non-specified tinnitus in PPI users, compared to non-users. Conclusion: Even if a favourable effect on this symptom derived from the treatment of gastroesophageal reflux cannot be excluded, a direct regulatory effect on inner ear homeostasis, through the action of PPI on the gastric type proton pump of the inner ear, cannot be ruled out. Another possible effect could depend upon vasomotor activity enabling better peripheral perfusion without significantly modifying blood pressure values, thus contributing to the stabilization of inner ear oxygenation. Additionally, a certain degree of anti-inflammatory effect could yield another kind of non-specific favourable influx. In conclusion, even if the supposed benefit deriving from the use of PPI in treating inner ear affections of unknown origin is still unclear with regard to its significance and limits, the reported results demonstrate that longitudinal studies could be useful in order to verify the possibility of a new therapeutic perspective.
引用
收藏
页码:84 / 87
页数:4
相关论文
共 50 条
  • [1] Proton pump inhibitors (PPI)
    Gogl, Markus
    Troeltzsch, Matthias
    Troeltzsch, Markus
    Mueller, Sebastian
    IMPLANTOLOGIE, 2022, 30 (02): : 59 - 66
  • [2] Duodenal and pancreatic tissue microbiome profiles of PPI users and non-users
    Yoshida, Takeichi
    Dbouk, Mohamad
    Hirose, Katsuya
    Abou Diwan, Elizabeth
    Saba, Helena
    Dbouk, Ali
    Goggins, Michael
    PANCREATOLOGY, 2024, 24 (01) : 188 - 195
  • [3] Guidelines on optimizing the use of proton pump inhibitors: PPI stewardship
    Amit Kumar Dutta
    Abhinav Jain
    Vaneet Jearth
    Ramit Mahajan
    Manas Kumar Panigrahi
    Vishal Sharma
    Mahesh Kumar Goenka
    Rakesh Kochhar
    Govind Makharia
    Duvvur Nageshwar Reddy
    Richard Kirubakaran
    Vineet Ahuja
    Neha Berry
    Naresh Bhat
    Usha Dutta
    Uday Chand Ghoshal
    Ajay Jain
    Umesh Jalihal
    V. Jayanthi
    Ajay Kumar
    Sandeep Nijhawan
    Ujjal Poddar
    G. N. Ramesh
    Shivram P Singh
    Showkat Zargar
    Shobna Bhatia
    Indian Journal of Gastroenterology, 2023, 42 : 601 - 628
  • [4] Guidelines on optimizing the use of proton pump inhibitors: PPI stewardship
    Dutta, Amit Kumar
    Jain, Abhinav
    Jearth, Vaneet
    Mahajan, Ramit
    Panigrahi, Manas Kumar
    Sharma, Vishal
    Goenka, Mahesh Kumar
    Kochhar, Rakesh
    Makharia, Govind
    Reddy, Duvvur Nageshwar
    Kirubakaran, Richard
    Ahuja, Vineet
    Berry, Neha
    Bhat, Naresh
    Dutta, Usha
    Ghoshal, Uday Chand
    Jain, Ajay
    Jalihal, Umesh
    Jayanthi, V.
    Kumar, Ajay
    Nijhawan, Sandeep
    Poddar, Ujjal
    Ramesh, G. N.
    Singh, Shivram P.
    Zargar, Showkat
    Bhatia, Shobna
    INDIAN JOURNAL OF GASTROENTEROLOGY, 2023, 42 (05) : 601 - 628
  • [5] Clopidogrel and proton pump inhibitor (PPI) interaction: separate intake and a non-omeprazole PPI the solution?
    S. Kenngott
    R. Olze
    M. Kollmer
    H. Bottheim
    A. Laner
    E. Holinski-Feder
    M. Gross
    European Journal of Medical Research, 15
  • [6] CLOPIDOGREL AND PROTON PUMP INHIBITOR (PPI) INTERACTION: SEPARATE INTAKE AND A NON-OMEPRAZOLE PPI THE SOLUTION?
    Kenngott, S.
    Olze, R.
    Kollmer, M.
    Bottheim, H.
    Laner, A.
    Holinski-Feder, E.
    Gross, M.
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2010, 15 (05) : 220 - 224
  • [7] Strategies for discontinuation of proton pump inhibitors (PPIs) in patients with long-term PPI administration: a randomized controlled trial
    Mariko Hojo
    Daisuke Asaoka
    Yuji Shimada
    Shuko Nojiri
    Akihito Nagahara
    BMC Gastroenterology, 22
  • [8] Strategies for discontinuation of proton pump inhibitors (PPIs) in patients with long-term PPI administration: a randomized controlled trial
    Hojo, Mariko
    Asaoka, Daisuke
    Shimada, Yuji
    Nojiri, Shuko
    Nagahara, Akihito
    BMC GASTROENTEROLOGY, 2022, 22 (01)
  • [9] Reduziert arriba-PPI die Überversorgung mit Protonenpumpeninhibitoren? Eine MachbarkeitsstudieDoes arriba-PPI Reduce Overutilization of Proton Pump Inhibitors? A Feasibility Study
    Julia Heisig
    Susanne Friedrich
    Johanna Nikel
    Anne-Lisa Heye
    Anne Barzel
    Bettina Bücker
    Stefan Wilm
    Annika Viniol
    Norbert Donner-Banzhoff
    Annette Becker
    Zeitschrift für Allgemeinmedizin, 2022, 98 (1): : 8 - 12
  • [10] The Perilous PPI: Proton Pump Inhibitor as a Cause of Clinically Significant Hypomagnesaemia
    Tai, Yong Ting
    Tong, Chin Vong
    JOURNAL OF THE ASEAN FEDERATION OF ENDOCRINE SOCIETIES, 2020, 35 (01): : 109 - 113